Market News
Monday, July 25, 2016
BRIEF-Abbvie says CHMP grants positive opinion for shorter treatment duration with VIEKIRAX
* CHMP grants positive opinion for shorter treatment duration with Abbvie's VIEKIRAX
(ombitasvir/paritaprevir/ritonavir tablets) for patients with genotype 4 chronic hepatitis C
with compensated...
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment